**INTRODUCTION:** Despite the medical necessity, legislative mandates, and economic benefits of gender-affirming surgery, access to treatment remains limited. World Professional Association for Transgender Health (WPATH) has proposed guidelines for transition-related surgery in conjunction with criteria to delineate medical necessity. We assessed insurance coverage of "top" gender-affirming surgery and evaluated the differences between insurance policy criteria and WPATH recommendations.

**METHODS:** We conducted a cross-sectional analysis of insurance policies for coverage of top gender-affirming surgery. Insurance companies were selected based on their state enrolment data and market share. A web-based search and individual telephone interviews were conducted to identify the policy. Medical necessity criteria were abstracted from publicly available policies.

**RESULTS:** Of the 57 insurers evaluated, bilateral mastectomy (female-to-male) was covered by significantly more insurers than breast augmentation (male-to-female) (96% versus 68%; *P* \< 0.0001). Only 4% of companies used WPATH-consistent criteria. No criterion was universally required by insurers. Additional prerequisites for coverage that extended beyond WPATH guidelines for top surgery were continuous living in congruent gender role, 2 referring mental health professionals, and hormone therapy before surgery. Hormone therapy was required in a significantly higher proportion of male-to-female policies compared to female-to-male policies (90% versus 21%; *P* \< 0.0001).

**CONCLUSION:** In addition to the marked intercompany variation in criteria for insurance coverage which often deviated from WPATH recommendations, there are healthcare insurers who categorically deny access to top gender-affirming surgery. A greater evidence base is needed to provide further support for the medical necessity criteria in current use.
